Positive results for sustained-release bimatoprost implant

Allergan announced that its biodegradable sustained-release bimatoprost implant is comparable to daily topical bimatoprost.

The 6-month interim results from 75 glaucoma patients showed that the implant lowered IOP in 92% and 71% of glaucoma patients at 4 months and 6 months, respectively. Additionally, at 6 months, more than 70% of the implant eyes had not required topical pressure-lowering rescue medication or a second bimatoprost injection. There were also no serious adverse events.

The intracameral implant is administered using a prefilled, single-use applicator. This study is expected to conclude in the second half of 2018.